ELVN Stock Analysis: Buy, Sell, or Hold?
ELVN - Enliven Therapeutics, Inc. Common Stock
$54.81
0.86 (1.59%)
▲
5d:
+3.51%
30d:
+12.41%
90d:
+32.94%
BUY
MODERATE Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Aug 12, 2026
8d
Get Alerted When ELVN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: ELVN shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: ELVN shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: ELVN is currently trading at $54.81, which is considered slightly high relative to its 30-day fair value range of $48.56 to $52.90.
Technical Outlook: Technically, ELVN is in a strong uptrend. The price is approaching resistance at $55.81. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $66.89 (+22.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ELVN is in a strong uptrend. The price is approaching resistance at $55.81. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $66.89 (+22.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$48.56 -
$52.90
Company Quality Score
52/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
66.8%
All Signals
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 22.0% below Wall St target ($66.89)
Trading Range Analysis
30-Day Trading Range
$48.56 -
$52.90
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$51.39
Resistance Level
$55.82
Current Trend
Strong Uptrend
Technical data as of
Jul 31, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-23.57
Wall Street Target
$66.89
(+22.0%)
Share & Embed Analysis
Last updated: August 02, 2026 10:36 PM ET
Data refreshes hourly during market hours. Next update: 11:36 PM
Data refreshes hourly during market hours. Next update: 11:36 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ELVN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
3
Sells
Net
INSIDERS SELLING
Recent Transactions
Benjamin Hohl
SELL
10000 shares
2026-03-06
Richard A Heyman
SELL
1230 shares
2026-02-17
Joseph P Lyssikatos
SELL
5000 shares
2026-02-06
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$416 | 53 HOLD |
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$386 | 43 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$87 | 53 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$557 | 49 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$309 | 54 HOLD |
Advanced ELVN Option Strategies
Professional options setups generated by AI based on today's ELVN price and gamma walls.
